Mersana Therapeutics (MRSN) Price & Analysis

Compare

677 Followers

MRSN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.21 - $70.75

Previous CloseN/A

Volume429.52K

Average Volume (3M)46.26K

Market Cap

$39.73M

Enterprise Value-$19.93M

Total Cash (Recent Filing)$76.97M

Total Debt (Recent Filing)$20.62M

Price to Earnings (P/E)―

Beta2.90

Next Earnings

Nov 11, 2025

EPS Estimate

-1.54

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.87

Shares Outstanding4,990,692

10 Day Avg. Volume40,401

30 Day Avg. Volume46,262

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.50

Enterprise Value/Revenue-0.57

Enterprise Value/Gross Profit-0.58

Enterprise Value/Ebitda0.29

Forecast

1Y Price Target

$35.40

Price Target Upside275.00% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical Trials ProgressEmi-Le Phase 1 dose expansion has enrolled over 45 patients in post-topo TNBC, highlighting progress in clinical trials.

Financial MilestonesAchievement of a $15M development milestone from GSK for the XMT-2056 program was announced.

Liquidity And Cash RunwayThe $15M GSK milestone strengthens liquidity, extending cash runway into mid-2026 providing operational visibility through multiple readouts.

Bears Say

Financial ConstraintsCompany has approximately 0.8 years of cash left, indicating potential financial constraints.

Investor SentimentInvestors' current aversion to this story is partially driven by historical experiences with prior ADC platforms and prior management.

Skepticism And UncertaintySkepticism over whether Emi-Le could realize an actionable therapeutic window due to doubts about proteinuria claims.

Mersana Therapeutics News

Buy Rating for Mersana Therapeutics: Promising Potential in Post-Topo TNBC with Emi-Le ADC

Mersana Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Charles Zhu from...

2d ago

MRSN

Mersana Therapeutics Faces Nasdaq Non-Compliance Notice

The latest announcement is out from Mersana Therapeutics ( ($MRSN) ). On September 5, 2025, Mersana Therapeutics received...

1M ago

MRSN

Mersana Therapeutics’ Earnings Call Highlights Progress and Challenges

Mersana Therapeutics (($MRSN)) has held its Q2 earnings call. Read on for the main highlights of the call....

1M ago

MRSN

Mersana Therapeutics Positioned Favorably with Promising Developments and Strategic Adjustments Supporting Buy Rating

In a report released on August 13, Charles Zhu from LifeSci Capital maintained a Buy rating on Mersana...

2M ago

MRSN

Mersana Therapeutics price target adjusted to $36 at Truist after reverse split

Truist analyst Asthika Goonewardene lowered the firm’s price target on Mersana Therapeutics (MRSN) to $36 from $250 and...

2M ago

MRSN

Mersana Therapeutics Faces Financial Strain Amid U.S. Tariff Uncertainties

Mersana Therapeutics (MRSN) has disclosed a new risk, in the Capital Markets category. Mersana Therapeutics faces significant business...

2M ago

MRSN

Mersana Therapeutics Reports Q2 2025 Financial Results

Mersana Therapeutics ( ($MRSN) ) has released its Q2 earnings. Here is a breakdown of the information Mersana...

2M ago

MRSN

Mersana Therapeutics price target adjusted to $17 at BTIG after reverse split

BTIG adjusted the firm’s price target on Mersana Therapeutics (MRSN) to $17 from $6 and keeps a Buy...

2M ago

MRSN

Promising Progress and Strategic Focus Drive Buy Rating for Mersana Therapeutics

TD Cowen analyst Tara Bancroft has maintained their bullish stance on MRSN stock, giving a Buy rating today....

2M ago

MRSN

Mersana Therapeutics reports Q2 EPS ($4.87), consensus ($4.25)

Reports Q2 revenue $3.056M, consensus $6.06M. “During the second quarter, we were excited to have Emi-Le clinical data...

2M ago

MRSN

MRSN Upcoming Earnings Report: What to Expect?

Mersana Therapeutics (MRSN) is scheduled to report 2nd quarter earnings on 08/13/2025, before the market opens. Regarding Q2...

2M ago

MRSN

Upcoming Stock Splits This Week (July 28 to August 1) – Stay Invested

These are the upcoming stock splits for the week of July 28 to August 1, based on TipRanks’ Stock...

2M ago

AGRI

AIHS

Mersana Therapeutics trading halted, news pending

19:50 EDT Mersana Therapeutics (MRSN) trading halted, news pending Published first on TheFly – the ultimate source for...

3M ago

MRSN

Mersana Therapeutics Announces Reverse Stock Split

Mersana Therapeutics ( ($MRSN) ) just unveiled an update. On July 24, 2025, Mersana Therapeutics announced a 1-for-25...

3M ago

MRSN

MRSN FAQ

What was Mersana Therapeutics’s price range in the past 12 months?

Mersana Therapeutics lowest stock price was $5.21 and its highest was $70.75 in the past 12 months.

What is Mersana Therapeutics’s market cap?

Mersana Therapeutics’s market cap is $39.73M.

When is Mersana Therapeutics’s upcoming earnings report date?

Mersana Therapeutics’s upcoming earnings report date is Nov 11, 2025 which is in 32 days.

How were Mersana Therapeutics’s earnings last quarter?

Mersana Therapeutics released its earnings results on Aug 13, 2025. The company reported -$4.87 earnings per share for the quarter, missing the consensus estimate of -$3.865 by -$1.005.

Is Mersana Therapeutics overvalued?

According to Wall Street analysts Mersana Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mersana Therapeutics pay dividends?

Mersana Therapeutics does not currently pay dividends.

What is Mersana Therapeutics’s EPS estimate?

Mersana Therapeutics’s EPS estimate is -1.54.

How many shares outstanding does Mersana Therapeutics have?

Mersana Therapeutics has 4,990,692 shares outstanding.

What happened to Mersana Therapeutics’s price movement after its last earnings report?

Mersana Therapeutics reported an EPS of -$4.87 in its last earnings report, missing expectations of -$3.865. Following the earnings report the stock price went up 12.191%.

Which hedge fund is a major shareholder of Mersana Therapeutics?

Currently, no hedge funds are holding shares in MRSN

Mersana Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-505.14%

Trailing 12-Months

Asset Growth

-52.79%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mersana Therapeutics

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Mersana Therapeutics (MRSN) Earnings & Revenues

Historic Earnings Reports

MRSN Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call highlighted significant progress in clinical trials and milestone achievements, especially in the Emi-Le and XMT-2056 programs. However, challenges remain with proteinuria management and modest revenue growth, balanced by a stable financial outlook.View all MRSN earnings summaries

MRSN Stock 12 Month Forecast

Average Price Target

$35.40

▲(275.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","58":"$58","18.25":"$18.25","31.5":"$31.5","44.75":"$44.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,18.25,31.5,44.75,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.94,11.175384615384615,14.410769230769231,17.646153846153847,20.88153846153846,24.11692307692308,27.352307692307694,30.58769230769231,33.823076923076925,37.058461538461536,40.293846153846154,43.52923076923077,46.76461538461538,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.94,10.052307692307693,12.164615384615384,14.276923076923076,16.389230769230767,18.50153846153846,20.613846153846154,22.726153846153846,24.838461538461537,26.95076923076923,29.06307692307692,31.175384615384612,33.2876923076923,{"y":35.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.94,8.636923076923077,9.333846153846155,10.03076923076923,10.727692307692308,11.424615384615384,12.121538461538462,12.818461538461538,13.515384615384615,14.212307692307693,14.909230769230769,15.606153846153845,16.303076923076922,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.5,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.75,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.36,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.98,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.02,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.94,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >